Bioretec is?developing?the new RemeOs™?product line?based on a magnesium alloy and hybrid composite, introducing a new generation of strong bioresorbable materials for enhanced surgical outcomes. The RemeOs™ implants are resorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on?value for patients through efficient healthcare. With the U.S. and EU market authorization for the first RemeOs™ product expected in 2022, Bioretec is positioning itself to enter the addressable USD 7 billion global orthopedic trauma market and become a game changer in surgical possibilities. Better Healing – Better Life. www.bioretec.com
Appendix
Bioretec Ltd half year report January – June 2022 (PDF)
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/bioretec/r/bioretec-ltd-s-half-year-report-2022–unaudited–strong-sales-growth-and-remeos–registrations-on-go,c3613176
The following files are available for download: